Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets

• Published in: ESMO open 2024-10, Vol.9 (10), p.103706, Article 103706
• Main Authors: Kehmann, L., Jördens, M., Loosen, S.H., Luedde, T., Roderburg, C., Leyh, C.
• Format: Article
• Language: English
• Subjects: biliary tract cancer; FGFR2; IDH1; precision oncology; Review; targeted therapy
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2024.103706

Biliary tract cancer, the second most common type of liver cancer, remains a therapeutic challenge due to its late diagnosis and poor prognosis. In recent years, it has become evident that classical chemotherapy might not be the optimal treatment for patients with biliary tract cancer, especially after failure of first-line therapy. Finding new treatment options and strategies to improve the survival of these patients is therefore crucial. With the rise and increasing availability of genetic testing in patients with tumor, novel treatment approaches targeting specific genetic alterations have recently been proposed and have demonstrated their safety and efficacy in numerous clinical trials. In this review, we will first consider chemotherapy options and the new possibility of combining chemotherapy with immune checkpoint inhibitors in first-line treatment. We will then provide an overview of genomic alterations and their potential for targeted therapy especially in second-line therapy. In addition to the most common alterations such as isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, fibroblast growth factor receptor 2 (FGFR2) fusions, and alterations, we will also discuss less frequently encountered alterations such as BRAF V600E mutation and neurotrophic tyrosine kinase receptor gene (NTRK) fusion. We highlight the importance of molecular profiling in guiding therapeutic decisions and emphasize the need for continued research to optimize and expand targeted treatment strategies for this aggressive malignancy. •Biliary tract cancer is often associated with genetic alterations and is an excellent model for precision oncology.•The most common targetable alterations are IDH1 and 2 mutations as well as FGFR2 fusions or rearrangements.•This review summarizes novel therapeutic options for targeted therapy in advanced biliary tract cancer.